• Webinar recorded on Thu 25th October, 2012
  • 1 hours 6 mins
  • No Comments

The first description of Feline Injection Site Sarcoma (FISS) was by Hendrick, and Goldschmidt in 1991 and was originally termed Vaccine-Associated Sarcoma, as the original epidemiological data in the USA suggested a strong association between the disease and vaccination with either Rabies or Feline Leukeamia virus (FeLV) vaccines.  Since this time, studies investigating the pathophysiology of this disease have indicated that any foreign material injected into cats that can cause local and intense inflammatory response could lead to this disease.   The disease has been reported all over the world with varying incidence.  However, the main characteristics of this disease remain constant.  It is a disease of low metastatic potential but is highly locally invasive.  Often there is a significant lag period between the injection, and the ultimate development of a tumour.  However, once the tumour develops, there is often observed a period of rapid growth.  Single modality therapy is rarely curative, and sophisticated imaging technologies are required to determine the extent of disease prior to treatment.  The pathogenesis of this disease is still poorly understood but has led to a number of recommendations in terms of vaccination strategies and how to manage post-vaccination lumps.  The aim of this short synopsis is to present our current understanding of this disease and how that influences the clinical decisions we make.  Specifically we will focus on:

  • The current thinking on vaccine choice and vaccine recommendations in cats
  • Decision making for post vaccine lumps
  • Decision making if a tumour develops, including clinical approach and imaging modalities
  • The role of surgery in this disease and the controversial roles of chemotherapy and radiation.  We will include in this the possible use of the new tyrosine kinase inhibitors.

Finally we will discuss some other challenging mesenchymal tumours in cats.

Read More

Please consider one of the following membership levels to enable you to view this webinar...